Suppr超能文献

焦磷酸测序分析检测甲状腺结节细针穿刺抽吸活检标本中的BRAFV600E突变。

Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.

作者信息

Kim Suk Kyeong, Kim Dong-Lim, Han Hye Seung, Kim Wan Seop, Kim Seung Ja, Moon Won Jin, Oh Seo Young, Hwang Tae Sook

机构信息

Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.

出版信息

Diagn Mol Pathol. 2008 Jun;17(2):118-25. doi: 10.1097/PDM.0b013e31815d059d.

Abstract

BACKGROUND

Fine-needle aspiration biopsy (FNAB) is the primary means of distinguishing benign from malignant and of guiding therapeutic intervention in thyroid nodules. However, 10% to 30% of cases with indeterminate cytology in FNAB need other diagnostic tools to refine diagnosis.

OBJECTIVE

We compared the pyrosequencing method with the conventional direct DNA sequencing analysis and investigated the usefulness of preoperative BRAF mutation analysis as an adjunct diagnostic tool with routine FNAB.

METHODS

A total of 103 surgically confirmed patients' FNA slides were recruited and DNA was extracted after atypical cells were scraped from the slides. BRAF mutation was analyzed by pyrosequencing and direct DNA sequencing.

RESULTS

Sixty-three (77.8%) of 81 histopathologically diagnosed malignant nodules revealed positive BRAF mutation on pyrosequencing analysis. In detail, 63 (84.0%) of 75 papillary thyroid carcinoma (PTC) samples showed positive BRAF mutation, whereas 3 follicular thyroid carcinomas, 1 anaplastic carcinoma, 1 medullary thyroid carcinoma, and 1 metastatic lung carcinoma did not show BRAF mutation. None of 22 benign nodules had BRAF mutation in both pyrosequencing and direct DNA sequencing. Out of 27 thyroid nodules classified as 'indeterminate' on cytologic examination preoperatively, 21 (77.8%) cases turned out to be malignant: 18 PTCs (including 2 follicular variant types) and 3 follicular thyroid carcinomas. Among these, 13 (61.9%) classic PTCs had BRAF mutation. None of 6 benign nodules, including 3 follicular adenomas and 3 nodular hyperplasias, had BRAF mutation. Among 63 PTCs with positive BRAF mutation detected by pyrosequencing analysis, 3 cases did not show BRAF mutation by direct DNA sequencing. Although it was not statistically significant, pyrosequencing was superior to direct DNA sequencing in detecting the BRAF mutation of thyroid nodules (P=0.25).

CONCLUSION

Detecting BRAF mutation by pyrosequencing is more sensitive, faster, and less expensive than direct DNA sequencing and is proposed as an adjunct diagnostic tool in evaluating thyroid nodules of indeterminate cytology.

摘要

背景

细针穿刺活检(FNAB)是区分甲状腺结节良恶性以及指导治疗干预的主要手段。然而,FNAB中10%至30%的细胞学结果不确定的病例需要其他诊断工具来完善诊断。

目的

我们将焦磷酸测序法与传统的直接DNA测序分析进行比较,并研究术前BRAF突变分析作为常规FNAB辅助诊断工具的实用性。

方法

共收集103例经手术证实的患者的FNA涂片,从涂片上刮取非典型细胞后提取DNA。通过焦磷酸测序和直接DNA测序分析BRAF突变。

结果

在81例经组织病理学诊断为恶性的结节中,63例(77.8%)在焦磷酸测序分析中显示BRAF突变阳性。具体而言,75例甲状腺乳头状癌(PTC)样本中有63例(84.0%)显示BRAF突变阳性,而3例滤泡状甲状腺癌、1例未分化癌、1例髓样甲状腺癌和1例肺转移癌未显示BRAF突变。22例良性结节在焦磷酸测序和直接DNA测序中均未检测到BRAF突变。术前细胞学检查分类为“不确定”的27例甲状腺结节中,21例(77.8%)最终被证实为恶性:18例PTC(包括2例滤泡变体类型)和3例滤泡状甲状腺癌。其中,13例(61.9%)经典PTC有BRAF突变。6例良性结节,包括3例滤泡性腺瘤和3例结节性增生,均未检测到BRAF突变。在焦磷酸测序分析检测到BRAF突变阳性的63例PTC中,有3例通过直接DNA测序未显示BRAF突变。虽然差异无统计学意义,但焦磷酸测序在检测甲状腺结节的BRAF突变方面优于直接DNA测序(P=0.25)。

结论

与直接DNA测序相比,焦磷酸测序检测BRAF突变更敏感、更快速且成本更低,建议作为评估细胞学结果不确定的甲状腺结节的辅助诊断工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验